ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

ImageneBio IncNASDAQ: IMA

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow turns negative

Q1 FY2026 financing cash flow was -$3.24M, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $132.22M. Over 3 fiscal years it compounded at +398.3% a year.

Context

  • Financing cash flow amounted to 16933.5% of revenue in FY2025, up 16933.5 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near -$3.24M or moves back toward the trailing-twelve-month quarterly average of $33.06M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.24M— QoQ
Last fiscal yearDec 2025
$135.47M— YoY
LTMMar 2026
$132.22M— YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR+398.3%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
135.47M USD
Year-over-year change
—
4-year CAGR
+0.7%

Financing Cash Flow vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Over three fiscal years its annual growth of +398.3% compares with a peer median of +143.3%.
IMA Competitors
Financing Cash Flow for IMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OVIDOvid Therapeutics Inc.LTM Mar 2026$164.18M USD+40238.1%+646.7%2305.2%
IMAImageneBio IncLTM Mar 2026$132.22M USD—+398.3%—
STROSutro Biopharma, Inc.LTM Mar 2026$103.05M USD+5.6%-90.3%103.5%
STTKShattuck Labs, Inc.LTM Mar 2026$70.43M USD+7606.1%+538.8%7043.4%
KLRSKalaris Therapeutics IncLTM Mar 2026$52.42M USD—+132.0%—
IFRXInflaRx N.V.LTM Mar 2026€6.23M EUR-77.3%+154.7%21245.3%
CNTBConnect Biopharma Holdings LimitedFY2025$1.09M USD+381.5%—1707.8%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$342K USD-100.2%——
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD-100.0%-46.9%—
Peer median (excluding IMA) —+5.6%+143.3%2305.2%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.12M)(68.77M)(68.17M)(49.23M)(52.4M)
Depreciation & Amortization544K751K1.02M490K328K
Deferred Income Tax00000
Stock-Based Compensation5.18M7.53M05.3M15.39M
Change in Working Capital(33.03M)(15.14M)(21.67M)(3.98M)(19.19M)
Accounts Receivables361K(291K)000
Inventory00000
Accounts Payables00(2.87M)(1.17M)(2.82M)
Other Working Capital(33.39M)(14.85M)(18.8M)(2.81M)(16.37M)
Other Non-Cash Items1.17M1.52M9.07M1.42M8.02M
Operating Cash Flow(60.25M)(74.11M)(79.74M)(46M)(47.84M)
Capital Expenditures(1.76M)(1.43M)(414K)00
Acquisitions (Net)0000(5.22M)
Purchases of Investments0(216.34M)(90.05M)(88.3M)(10.4M)
Sales of Investments0118.49M154.61M60.46M9.8M
Other Investing Activities000(7.07M)0
Investing Cash Flow(1.76M)(99.28M)64.14M(34.9M)(5.81M)
Debt Repayment000015M
Common Stock Issued131.3M037.56M065.84M
Common Stock Repurchased00(663K)00
Dividends Paid00000
Other Financing Activities582K1.1M39.09M054.63M
Financing Cash Flow131.74M1.1M75.98M0135.47M
Effect of Forex Changes00(406K)0604K
Net Change in Cash69.73M(172.3M)59.98M(80.91M)82.41M
Free Cash Flow(62.01M)(75.54M)(80.16M)(46M)(47.84M)

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.